Tamtam Try Tamtam free
Gedeon Richter logo

Gedeon Richter account plan

Pharmaceutical manufacturing and research

At a glance

Gedeon Richter is a Budapest-listed pharmaceutical group with FY2025 revenues of HUF 928,962m (EUR 2,336.1m) and 11,955 employees in 50+ countries.

Gedeon Richter Plc. is a Hungarian pharmaceutical group, founded in 1901 and listed in Budapest, that develops, makes and sells original drugs, generics, biosimilars and contract biologics manufacturing (CDMO). It is organised in an Innovative pillar (Women's Healthcare and Neuropsychiatry) and an Affordable pillar (General Medicines and Biotechnology), and sells in more than 50 countries; the USA, Russia, Hungary, Poland and Germany are its top markets. In FY2025 it reported revenues of HUF 928,962m (EUR 2,336.1m, +8.3%), EBIT of HUF 292,851m and net profit of HUF 232,335m. It had 11,955 employees at end-2025, including more than 1,100 in R&D. Its largest shareholders are two Hungarian foundations with 10.00% each, and international investors held 59.66% of the shares.

Business units

Strategic priorities

Richter 2035 non-CNS growth
Grow non-CNS revenues 7-8% a year to around EUR 3.2-3.5bn by 2035, ahead of the VRAYLAR US exclusivity end on 17 March 2030.
Non-CNS margin of 20%+
Lift the non-CNS Clean EBIT margin to 20%+ by 2030-31 by fixing Biotechnology, building WHC and GM portfolios and running commercial effectiveness and efficiency programmes.
Women's Healthcare leadership and US entry
Become the leading gynaecological company in Europe by the end of the decade, and bring FYLREVY to the US market in 2027, with a partner or alone.
Biotechnology to break-even
Scale biosimilar launches (denosumab, tocilizumab) toward self-sustaining operation; steady-state break-even was targeted by end-2027 and the unit broke even in Q3 2026.
General Medicines portfolio renewal
Return GM to steady mid-single-digit growth, driven by NOACs and a GLP-1 portfolio built with Adalvo and Hetero.
External innovation and M&A
Spend roughly as much on M&A and licensing as on internal R&D over 10 years, mainly in women's health, while keeping a dividend floor of about EUR 200m after the VRAYLAR LoE.

Latest results

In Q1-Q3 2026 (to 30 September), pharma revenues were HUF 686.5bn, +2.6% reported but +11.7% at constant exchange rates, as the strong forint cost about 9 percentage points. Pharma Clean EBIT rose to HUF 229.9bn (+25% CER), EBIT to HUF 216.8bn (+6.0%) and net profit to HUF 174.9bn (+7.1%), with record free cash flow of HUF 223bn. CNS revenues grew 19% CER, WHC 10.9% CER and Biotechnology 34.9% CER, while General Medicines grew only 1.4% CER. Guidance for 2026 was raised again in November 2026 to pharma revenue growth above 10% CER and high-teens pharma Clean EBIT growth (CER).

Investments and deals

Women's health deals
Mithra deal (EV EUR 175m, 2024) for the estetrol platform, a stake in US fertility company Granata Bio (May 2025), and the acquisition of Celmatix's women's health discovery portfolio (March 2026).
GLP-1 partnerships
Global semaglutide co-development with Adalvo (May 2025) and a global semaglutide partnership with Hetero (June 2026).
API manufacturing restructuring
Budapest API manufacturing shrinks from four plants to one half, with production concentrated in Dorog; API energy use is down 54%.
Lenzetto capacity
Richter is investing in manufacturing capacity because Lenzetto demand outruns supply, and repurchased earlier royalty liabilities.
Transformation programmes
Cloud ERP/SAP and similar transformation and restructuring costs, estimated at EUR 10-20 million for 2026, are excluded from Clean EBIT; restructuring expenses were HUF 8.8bn in Q1-Q3 2026.

Challenges and risks

Cariprazine concentration
Neuropsychiatry earns about three-quarters of pharma Clean EBIT, mostly from VRAYLAR royalties via AbbVie, and US exclusivity ends on 17 March 2030.
Currency headwinds
The strong forint cost about 9 percentage points of reported revenue growth in 2026, and FX losses cut net profit in FY2025 and H1 2026.
US pricing and tariffs
US drug-price pressure (Medicare renegotiation, MFN) and tariffs are flagged as strategic risks.
Russia and Eastern Europe exposure
Russia is the No. 2 market (HUF 137,056m in FY2025), carrying war, sanctions, supply and cash-flow risks.
Supply and manufacturing issues
A MYDOCALM/MYDETON out-of-stock and injectables issues hurt General Medicines, Lenzetto faces temporary stock-outs, and the USYMRO launch was put on hold over a partner's GMP issue.

What leadership says

“Hormones are the future.”

Gábor Orbán, Chief Executive Officer · Q4 2025 earnings call, 26 February 2026

“Our commitment is to bring FYLREVY to the market in 2027”

Gábor Orbán, Chief Executive Officer · Q2 2026 earnings call, 7 August 2026

“We are in overhead fighting mode”

Gábor Orbán, Chief Executive Officer · Q2 2026 earnings call, 7 August 2026, on API restructuring and centralised services

“There is no other Hungary-based company with both products and personnel present on all five continents—only Richter.”

Gábor Orbán, Chief Executive Officer · Interview with Hungarian Conservative, 26 May 2025

Where a supplier can help

Manufacturing capacity and supply reliability
Lenzetto stock-outs, the GM out-of-stock and the capacity investments point to needs in production scale-up, supply planning and quality systems.
Efficiency and transformation services
The non-CNS margin goal and the overhead push (centralised services, cloud ERP/SAP, R&D efficiency with AI) open doors for process, IT and automation suppliers.
US launch support for FYLREVY
The 2027 US launch target, with partnering in progress, creates needs in regulatory, market access and commercial launch services.
Biosimilar commercialisation
Biotechnology's push to break-even with new biosimilar launches and price-competitive tenders calls for pricing, tender and supply-chain support.
FX and treasury tools
Repeated FX losses on USD revenues are a stated headwind, a fit for hedging and treasury analytics providers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Gedeon Richter?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Gedeon Richter

What does Gedeon Richter do?

Gedeon Richter is a Hungarian pharmaceutical group that develops, manufactures and sells original drugs, generics, biosimilars and CDMO services. Its four units are Women's Healthcare, Neuropsychiatry, General Medicines and Biotechnology.

What is Gedeon Richter's revenue?

FY2025 revenues were HUF 928,962m (EUR 2,336.1m), up 8.3%. In Q1-Q3 2026 pharma revenues were HUF 686.5bn, +11.7% at constant exchange rates.

How many employees does Gedeon Richter have?

It had 11,955 employees at end-2025, 6,097 of them in Hungary, with more than 1,100 working in R&D.

What is Gedeon Richter's strategy?

Richter 2035 aims to grow non-CNS revenues to around EUR 3.2-3.5bn by 2035 and lift the non-CNS Clean EBIT margin to 20%+ by 2030-31, preparing for the end of VRAYLAR US exclusivity in 2030. Women's Healthcare is the main growth and M&A focus.

Who leads Gedeon Richter?

Gábor Orbán has been CEO since 2017 and László András Kovács is CFO. Prof. Dr. E. Szilveszter Vizi chairs the Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)